InMed Pharmaceuticals reported financial results for Q1 FY2025 ended September 30, 2024. BayMedica commercial business generated revenues of $1.3M, a 40% YoY increase, with $0.3M net income. The company's cash position stood at $5.6M as of September 30, 2024.InMed's Alzheimer's treatment candidate, INM-901, showed promising results in long-term preclinical studies, achieving statistical significance in certain behavioral criteria. The drug demonstrated oral bioavailability comparable to intraperitoneal injection. Further molecular analyses are expected in Q4 2024. The dry AMD candidate, INM-089, is progressing towards GLP studies.The company implemented a reverse stock split to regain Nasdaq compliance, effective November 14, 2024. InMed expects its current cash to fund operations through Q1 2025, depending on BayMedica revenues and operating expenses. R&D expenses are anticipated to increase in 2025 as the company advances its preclinical work and IND-enabling studies.

InMed Pharmaceuticals reported financial results for Q1 FY2025 ended September 30, 2024. BayMedica commercial business generated revenues of $1.3M, a 40% YoY increase, with $0.3M net income. The company's cash position stood at $5.6M as of September 30, 2024.InMed's Alzheimer's treatment candidate, INM-901, showed promising results in long-term preclinical studies, achieving statistical significance in certain behavioral criteria. The drug demonstrated oral bioavailability comparable to intraperitoneal injection. Further molecular analyses are expected in Q4 2024. The dry AMD candidate, INM-089, is progressing towards GLP studies.The company implemented a reverse stock split to regain Nasdaq compliance, effective November 14, 2024. InMed expects its current cash to fund operations through Q1 2025, depending on BayMedica revenues and operating expenses. R&D expenses are anticipated to increase in 2025 as the company advances its preclinical work and IND-enabling studies.